Info

Alnis is currently developing proprietary MagNaGel nanoparticles that combine diagnostic, drug and device capabilities to better detect, characterize and treat cancer. MagNaGel nanoparticles approximate the size and tumor-targeting capabilities of monoclonal antibodies. The nanoparticles are also comprised of magnetic crystals which enable several functions, including the use of MRI to track nanoparticles in the body.